JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01877 JUNSHI BIO

Not Yet Opened 11-12 16:08:06

15.740

+0.070

+0.45%

High15.960	Low15.330	Vol1.40M
Open15.700	D1 Closing15.670	Amplitude4.02%
Mkt Cap16.16B	Tradable Cap4.09B	Total Shares1.03B
T/O21.94M	T/O Rate0.54%	Tradable Shares260.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":15.74,"timestamp":1794470886004,"preClose":15.67,"halted":0,"volume":1398200,"delay":0,"changeRate":0.004467134652201677,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"Not Yet Opened","change":0.07,"latestTime":"11-12 16:08:06","open":15.7,"high":15.96,"low":15.33,"amount":21944488,"amplitude":0.040204,"askPrice":15.74,"askSize":5200,"bidPrice":15.69,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":-0.448,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":0,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":15.67,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":1.1060445310062055,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":30.8,"timestamp":1794466800000,"preClose":30.67,"halted":0,"volume":10061300,"delay":0,"premium":"-56.52"}},"requestUrl":"/m/hq/s/01877/tweets","defaultTab":"tweets","newsList":[{"id":"1123456946","title":"European Capital Groups Flock to China for Deals as Chinese Innovative Drugs Enter Overseas Commercialization 4.0 Era (Concept Stocks Attached)","url":"https://stock-news.laohu8.com/highlight/detail?id=1123456946","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123456946?lang=en_us&edition=fundamental","pubTime":"2026-11-09 07:26","pubTimestamp":1794180384,"startTime":"0","endTime":"0","summary":"According to a report, at the recently held \"FHIM2026 Global Pharmaceutical Cooperation and Investment Annual Conference\" in Shanghai, heads of more than 10 European life sciences investment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01877","01276","LU0359201612.USD","BK4585","06160","LU1023057109.AUD","LU0359201885.HKD","VXUS","LU0307460666.USD","LU1770034418.SGD","LU1969619763.USD","BK1588","KCAI","BK1500","BK4588","LU1303224171.USD","KURE","LU0828237510.HKD","BK1161","LU1251922891.USD","LU0228659784.USD","LU2543165471.USD","BK1574","LU2328871848.SGD","09969","BK1191","LU0588546209.SGD","BK1515","LU0359202008.SGD","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188277574","title":"JUNSHI BIO Registers Zero Share Movement in October 2026 and Reaffirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1188277574","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188277574?lang=en_us&edition=fundamental","pubTime":"2026-11-04 16:41","pubTimestamp":1793781716,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its Monthly Return for the period ended 31 October 2026, showing no changes in either authorised capital or issued share counts across its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679002276","title":"Shanghai Junshi Biosciences Could Be 75% Below Fair Value As Losses Narrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2679002276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679002276?lang=en_us&edition=fundamental","pubTime":"2026-10-31 19:34","pubTimestamp":1793446485,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences (SEHK:1877) just paired a new earnings update with fresh clinical news. Nine-month sales reached CNY 2,513.41 million, while the reported net loss narrowed to CNY 149.2 million.\nDespite the fresh clinical updates and narrowing nine month loss, Shanghai Junshi Biosciences’ share price has come under pressure, with a 30 day share price return down 20.93% and a year to date share price return down 31.51% at HK$15.26. The longer view also reflects investor caution,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-could-be-75-below-fair-value-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-could-be-75-below-fair-value-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1515","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679765218","title":"Shanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2679765218","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679765218?lang=en_us&edition=fundamental","pubTime":"2026-10-30 18:27","pubTimestamp":1793356052,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥170.9 million and basic earnings per share back in the red at ¥0.21 loss per share.\nShort term traders see another biotech setback. Longer term investors will focus on the bigger question that now hangs over Junshi: whether a loss making quarter interrupts the path implied by forecasts that point to...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JOYT","PMDE","01877","VGFPF","BK1515","GXDW","RGLO","BK1161","VOTE","BK1583","FEBU","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145975459","title":"JUNSHI BIO Narrows Net Loss Attributable to Shareholders by 75% to RMB 149 Million in First Three Quarters","url":"https://stock-news.laohu8.com/highlight/detail?id=1145975459","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145975459?lang=en_us&edition=fundamental","pubTime":"2026-10-29 21:40","pubTimestamp":1793281215,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) has released an announcement revealing that in the first three quarters of 2026, the company recorded operating revenue of RMB 2.513 billion, representing a year-on-year increase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1583","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166855199","title":"Junshi Biosciences Announces First Patient Dosed in Phase III Trial of JS207 Combined with JS007 for First-Line Treatment of Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166855199","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166855199?lang=en_us&edition=fundamental","pubTime":"2026-10-29 20:20","pubTimestamp":1793276427,"startTime":"0","endTime":"0","summary":"Junshi Biosciences (01877) has issued an announcement that the first patient has been dosed in a multicenter, randomized, controlled, open-label Phase III clinical study (referred to as the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","IBBQ","PSYK","BK1515","BK1161","BMED","BK1583","IBBJ","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125712085","title":"Hong Kong Stock Announcement Highlights: Ping An's First Three Quarters Net Profit Attributable to Shareholders Reaches 96.645 Billion Yuan, Continues to Deepen \"Comprehensive Finance + Healthcare and Elderly Care\" Dual-Wheel Parallel, Technology-Driven Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1125712085","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125712085?lang=en_us&edition=fundamental","pubTime":"2026-10-29 09:10","pubTimestamp":1793236231,"startTime":"0","endTime":"0","summary":"Major Developments:Ascletis Pharma-B (01672): GLP-1 oral small molecule ASC30 achieved a placebo-corrected HbA1c reduction of 1.7% at week 12 in U.S. Phase II study in diabetic subjects. Junshi...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0384037296.USD","LU0164880469.USD","LU0307460666.USD","LU0648948544.HKD","LU1880383440.USD","LU0405327494.USD","LU0856984785.SGD","LU1655091459.SGD","LU2348773727.SGD","LU0819123356.HKD","BK1171","IE00BVYPNQ40.USD","LU0862451753.SGD","LU1152091754.HKD","LU0540923850.HKD","LU0348735423.USD","LU0043850808.USD","LU1064131003.USD","LU0762540952.USD","LU0359202008.SGD","LU1282649141.HKD","LU1282649067.USD","LU1813983027.USD","LU1226287529.USD","LU0164872284.USD","LU0588546209.SGD","LU0831093199.SGD","IE00BMCWC346.EUR","LU0326950275.SGD","LU0588545730.USD","LU1720050803.USD","LU0651946864.USD","601318","BK4166","LU1008478684.HKD","01333","IE00B031HY20.USD","LU0831103253.SGD","LU2213484517.USD","LU0348788117.USD","LU0634319403.HKD","LU0348783233.USD","LU1282651048.USD","LU1366334651.USD","LU1044875133.USD","LU1051769294.HKD","SG9999002562.SGD","LU2039709279.SGD","LU0084288322.USD","LU0823426308.USD","LU1282649810.SGD","HK0000181112.HKD","LU0918141705.HKD","IE00BVYPNP33.GBP","LU0828237510.HKD","LU2476274308.USD","LU0117841782.USD","LU1642822792.SGD","LU0762541174.USD","BK1592","LU","LU1064130708.USD","VXUS","LU1224444064.USD","IE00BYV24P56.USD","LU0163747925.USD","SG9999000459.SGD","LU0797268264.HKD","LU0370786039.SGD","LU0051755006.USD","LU0417516571.SGD","LU0072462343.USD","03145","LU0164865239.USD","IE0008369823.USD","LU1048588211.SGD","LU1719994722.HKD","LU2399975544.HKD","LU0630378692.HKD","BK0196","IE00BZ08YS42.EUR","BK1184","LU1303224171.USD","LU1282648689.USD","LU1188198961.HKD","LU2153592121.USD","LU1831875114.USD","HK0000151867.HKD","BK1521","LU0561508036.HKD","LU0651947912.USD","LU1580142542.USD","LU2289578879.USD","LU0456827905.SGD","LU0650527681.SGD","LU0254981946.USD","IE00BZ08YT58.USD","LU1023057109.AUD","LU1794554557.SGD","LU1934453819.USD","SG9999014674.SGD","BK1610","LU0348805143.USD","LU1781817850.SGD","LU0918141887.USD","LU1515016050.SGD","IE0003895053.USD","HK0000306701.USD","LU0823426480.USD","LU1146622755.USD","LU1105468828.SGD","BK4504","IE00BGHQDM52.EUR","LU1993786604.SGD","BK1175","LU0878005551.USD","LU1044874839.SGD","LU0320764599.SGD","LU0878004406.USD","LU1235295612.USD","LU1282651121.HKD","LU0315179316.USD","LU0488056044.USD","LU0197773160.USD","LU1255011170.USD","LU0359201885.HKD","159940","HK0000286598.CNH","LU2148510915.USD","SG9999002828.SGD","LU1960683339.HKD","LU0140636845.USD","LU2348774022.SGD","82318","LU0449515922.USD","PAImain","LU0359201612.USD","BK0175","02318","LU0228659784.USD","LU0640798160.USD","LU1048596156.SGD","LU1770034418.SGD","BK0188","HK0000320223.HKD","LU0501845795.SGD","LU0708995583.HKD","HK0000306685.HKD","LU1769817179.HKD","LU0048580855.USD","LU0594300419.USD","LU1044876610.USD","LU2293587155.HKD","IE00B29SXG58.USD","LU0106959298.USD","BK1574","LU1997245177.USD","BK4526","LU0011963245.USD","LU2294711473.HKD","LU1115378108.SGD","159891","01877","IE0034224299.USD","HK0001040168.HKD","LU0791590937.USD","LU1655091616.SGD","LU1979443071.USD","LU0675040207.SGD","LU0890818403.SGD","LU0417516902.SGD","LU0149534421.HKD","LU1051768304.USD","LU1981816686.USD","LU2663582299.SGD","LU1046422090.SGD","LU0821914370.USD","LU1328277881.USD","BK0187","LU0315178854.USD","LU0228367735.SGD","LU0348783662.USD","LU0784639295.USD","SG9999004220.SGD","BK1507","LU0348784397.USD","LU0049853897.USD","LU0348825331.USD","LU0828237940.HKD","LU0117844026.USD","LU1807302812.USD","LU0327786744.USD","LU1820825898.SGD","LU0865486749.SGD","LU0463099449.HKD","LU0231483743.USD","LU1880383366.USD","LU0244354667.USD","LU2153591404.USD","LU2778985437.USD","HK0000320264.USD","BK1515","LU0348816934.USD","LU1997244956.HKD","BK0012","LU0791591158.USD","BK1114","LU0880133367.SGD","LU0328353924.USD","LU0882747503.HKD","LU0898667661.SGD","BK4588","SG9999002463.SGD","LU0149721374.USD","LU0072913022.USD","BK0070","BK1583","LU0039217434.USD","HK0001040143.USD","LU0572944931.SGD","LU1152091168.USD","LU0348814723.USD","LU0611395673.USD","LU1969619763.USD","LU2424517915.HKD","LU0819121731.USD","KCAI","LU0405327148.USD","PNGAY","LU2495084118.USD","LU1769817096.USD","LU0210527791.USD","LU0417516738.SGD","BK4585","LU0049112450.USD","LU2328871848.SGD","LU0605514214.HKD","LU0196878994.USD","LU1508157978.USD","LU0054450605.USD","LU0067412154.USD","LU1211504680.USD","BK0032","HPAD.SI","LU0210526637.USD","LU0588545904.SGD","LU1251922891.USD","BK0028","BK0207","LU0441854154.USD","LU0862451837.USD","HK0000181138.USD","LU0047713382.USD","LU0871576103.HKD","LU0630378429.USD","LU2152927971.USD","LU0235996351.USD","LU0348827113.USD","BK0183","BK1550","IE0005HP3H50.USD","IE0008368742.USD","IE00BF5LJ272.USD","LU0456846285.SGD","LU0594300179.USD","LU1481107354.HKD","LU0762542818.HKD","LU0181495838.USD","IE0032431581.USD","LU0607220059.USD","LU1366334578.USD","LU0293314216.USD","LU1961090484.USD","01672","LU1997245094.SGD","LU0588545490.SGD","LU0165289439.USD","LU0314109678.HKD","LU2226246903.HKD","LU2476274720.SGD","BK1512","BK1161","IE00BZ08YR35.GBP","LU0106252389.USD","LU0211977185.USD","LU0197773673.USD","LU0531971595.HKD","SG9999001903.USD","LU0052750758.USD","06110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122286303","title":"Junshi Biosciences Gains NMPA Acceptance for Subcutaneous Toripalimab NDA Targeting HER2-Positive Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1122286303","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122286303?lang=en_us&edition=fundamental","pubTime":"2026-10-28 22:02","pubTimestamp":1793196170,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) announced that China’s National Medical Products Administration (NMPA) has formally accepted the supplemental new drug application (sNDA)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678549692","title":"Shanghai Junshi Biosciences - Receives Supplemental Drug Approval from Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2678549692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678549692?lang=en_us&edition=fundamental","pubTime":"2026-10-28 21:49","pubTimestamp":1793195399,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nFWN46E21H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","01877","BK0239","688180","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678496198","title":"Shanghai Junshi Biosciences - Approval Granted for Toripalimab as Monotherapy for Advanced Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2678496198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678496198?lang=en_us&edition=fundamental","pubTime":"2026-10-28 21:49","pubTimestamp":1793195399,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nFWN46E21H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK0239","688180","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139237319","title":"Junshi Biosciences (01877) Receives Full Approval from NMPA for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Containing Chemotherapy Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1139237319","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139237319?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:18","pubTimestamp":1793189917,"startTime":"0","endTime":"0","summary":"Junshi Biosciences (01877) announced that the company recently received a Drug Supplementary Application Approval Notice issued by the National Medical Products Administration (NMPA), approving the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1515","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678156589","title":"Junshi Biosciences Doses First Patient in Phase III Trial of Lymphoma Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2678156589","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678156589?lang=en_us&edition=fundamental","pubTime":"2026-10-26 12:19","pubTimestamp":1792988361,"startTime":"0","endTime":"0","summary":"Junshi Biosciences  dosed the first patient in a phase III trial of JS203, its bispecific antibody candidate for relapsed or refractory diffuse large B-cell lymphoma.The trial will compare JS203 combined with chemotherapy against rituximab plus chemotherapy in 282 patients, according to a Friday Hong Kong bourse filing. Overall survival is the primary endpoint.Shares of the biopharmaceutical company fell 1% by midday Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","688180","BK1515","BK1583","01877","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128061464","title":"Junshi Biosciences Initiates Phase III Trial of Bispecific Antibody JS203 in Relapsed/Refractory DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=1128061464","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128061464?lang=en_us&edition=fundamental","pubTime":"2026-10-23 21:04","pubTimestamp":1792760681,"startTime":"0","endTime":"0","summary":"On 23 October 2026, Junshi Biosciences announced that the first patient has been dosed in its registrational, randomized, open-label, multicenter Phase III clinical study (JS203-003-III-DLBCL;...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137531218","title":"Junshi Biosciences Sets 29 October 2026 Board Meeting to Approve Nine-Month 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1137531218","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137531218?lang=en_us&edition=fundamental","pubTime":"2026-10-15 17:41","pubTimestamp":1792057309,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (abbreviated as Junshi Biosciences) has announced that its Board of Directors will convene on 29 October 2026 to consider and approve the Group’s unaudited...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176542821","title":"BNP PARIBAS SA Raises Stake in JUNSHI BIO by 204,800 Shares at HK$17.96 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1176542821","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176542821?lang=en_us&edition=fundamental","pubTime":"2026-10-05 08:00","pubTimestamp":1791158421,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on September 28, BNP PARIBAS SA increased its holdings in JUNSHI BIO (01877) by 204,800 shares at a price of HK$17.96 per share, for a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","EWH","BK1583","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122719111","title":"JUNSHI BIO: BNP PARIBAS SA Acquires Shares, Long Position Rises to 9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122719111","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122719111?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:33","pubTimestamp":1790933629,"startTime":"0","endTime":"0","summary":"On September 28, 2026, BNP PARIBAS SA bought 204,800 shares of JUNSHI BIO (H shares) on the SEHK open market at an average of HKD 17.96 per share, involving about HKD 3.68 million, and it is an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195660530","title":"Junshi Bio (01877) Surges Over 4% on Strategic Partnership with Meijie Medical to Explore \"Multimodal Drug-Device Combination\" in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1195660530","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195660530?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:50","pubTimestamp":1790736617,"startTime":"0","endTime":"0","summary":"Junshi Bio (01877) rose more than 4%, reaching 4.03% as of press time, at HK$19.09, with a turnover of HK$23.2684 million.On the news front, according to Junshi Bio's official WeChat account, the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06078","BK1515","VXUS","LU0329678170.USD","159891","LU0329678337.USD","BK1161","CNCR","LU2488822045.USD","BK4588","BK4585","CANC","LU0737861772.HKD","KCAI","BK1583","01877","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175034344","title":"Junshi Biosciences Swings to Profit on 45% Revenue Surge in 1H 2026, Boosted by Toripalimab Sales and Licensing Income","url":"https://stock-news.laohu8.com/highlight/detail?id=1175034344","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175034344?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:46","pubTimestamp":1790239591,"startTime":"0","endTime":"0","summary":"Shanghai-based Junshi Biosciences reported a sharp turnaround for the six months ended 30 June 2026, posting a profit attributable to shareholders of RMB25.50 million compared with a RMB413.43...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Junshi Biosciences Swings to Profit on 45% Revenue Surge in 1H 2026, Boosted by Toripalimab Sales and Licensing Income","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669458304","title":"Shanghai Junshi Biosciences Grants 715,000 A-Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2669458304","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669458304?lang=en_us&edition=fundamental","pubTime":"2026-09-24 09:34","pubTimestamp":1790213681,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  granted 715,000 A-share options to 16 participants under its 2025 A-Share Option Incentive Scheme, according to a Wednesday filing with the Hong Kong bourse.The options are exercisable into the same number of A-shares at 46.67 yuan apiece, with vesting periods of 12 or 24 months.Separately, 205 participants are eligible to exercise 11.5 million A-share options in the first exercise period.The company also plans to cancel 1.7 million A-share options following employee resignations and individual performance assessments.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","688180","01877","BK1515","BK1583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669768281","title":"Asian Growth Companies With High Insider Ownership September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669768281","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669768281?lang=en_us&edition=fundamental","pubTime":"2026-09-22 12:05","pubTimestamp":1790049930,"startTime":"0","endTime":"0","summary":"As of September 2026, Asian markets have been navigating a complex landscape influenced by global economic shifts and regional developments, with particular attention on the impact of rising energy costs and fluctuating demand in key sectors. Amidst these conditions, growth companies with high insider ownership have garnered interest for their potential resilience and alignment of interests between management and shareholders. In this context, identifying stocks that exhibit strong growth...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/materials/shse-600392/shenghe-resources-holding-shares/news/asian-growth-companies-with-high-insider-ownership-september-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/materials/shse-600392/shenghe-resources-holding-shares/news/asian-growth-companies-with-high-insider-ownership-september-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01877","DECU","VOTE","BK1583","PMDE","VGFPF","RGLO","GXDW","JOYT","BK1161","FEBU","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0642},{"period":"3month","weight":-0.1945},{"period":"6month","weight":-0.3364},{"period":"1year","weight":-0.3827},{"period":"ytd","weight":-0.2624}],"compareEarnings":[{"period":"1week","weight":-0.0318},{"period":"1month","weight":-0.0138},{"period":"3month","weight":-0.0441},{"period":"6month","weight":-0.0753},{"period":"1year","weight":-0.1082},{"period":"ytd","weight":-0.0633}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":-0.000677},{"month":8,"riseRate":0.125,"avgChangeRate":-0.039004},{"month":9,"riseRate":0.25,"avgChangeRate":-0.011976},{"month":10,"riseRate":0.25,"avgChangeRate":-0.030119},{"month":11,"riseRate":0.625,"avgChangeRate":0.042216},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"JUNSHI BIO","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"JUNSHI BIO,01877,JUNSHI BIO股票,JUNSHI BIO股票老虎,JUNSHI BIO股票老虎国际,JUNSHI BIO行情,JUNSHI BIO股票行情,JUNSHI BIO股价,JUNSHI BIO股市,JUNSHI BIO股票价格,JUNSHI BIO股票交易,JUNSHI BIO股票购买,JUNSHI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}